课题基金 / 基金详情

Aldosterone blockade for Health Improvement Evaluation in End-stage kidney disease: Extension

Aldosterone blockade for Health Improvement Evaluation in End-stage kidney disease: Extension
醛固酮阻断用于终末期肾病健康改善评估:延伸
批准号:
461992
负责人:
Walsh Michael W
金额:
$88.05万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2022
资助国家:
加拿大
项目状态:
未结题
起止时间:
2022-03-01 至 2027-03-01

项目摘要

项目成果

Walsh Michael W的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Almost 3 million people worldwide need dialysis to sustain their lives after their kidneys fail and this number is projected to double in the next 15 years. Almost half of patients that require dialysis for kidney failure die within three years mostly due
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glucocorticoids or Avacopan in peopLe with high-risk renal Anti-Neutrophil cytoplasm antibody associated vasculitis Trial (GALANT) - Pilot
  • 批准号:
    489796
  • 项目类别:
    Operating Grants
  • 资助金额:
    $37.9万
  • 财政年份:
    2023
  • 负责人:
    Walsh Michael W
  • 依托单位:
Protection of the heart with aldosterone antagonism in end-stage renal disease (PHASE 2) Trial
  • 批准号:
    333015
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2015
  • 负责人:
    Walsh Michael W
  • 依托单位:
Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: extended follow-up of a randomized controlled trial
  • 批准号:
    322606
  • 项目类别:
    Operating Grants
  • 资助金额:
    $24.76万
  • 财政年份:
    2015
  • 负责人:
    Walsh Michael W
  • 依托单位:
Protection of the heart with aldosterone antagonism in end-stage renal disease (PHASE 2) Trial
  • 批准号:
    310286
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2014
  • 负责人:
    Walsh Michael W
  • 依托单位:
海外基金